| PTGX Stock | | | USD 44.59 3.09 7.45% |
The current 90-days correlation between Protagonist Therapeutics and Unicycive Therapeutics is 0.33 (i.e., Weak diversification). The correlation of Protagonist Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Protagonist Therapeutics Correlation With Market
Significant diversification
The correlation between Protagonist Therapeutics and DJI is 0.09 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Protagonist Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in price.
For more information on how to buy Protagonist Stock please use our
How to Invest in Protagonist Therapeutics guide.
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.
High positive correlations | | High negative correlations |
Risk-Adjusted IndicatorsThere is a big difference between Protagonist Stock performing well and Protagonist Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Protagonist Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.